Cerevel Therapeutics Holdings (STU:673) Equity-to-Asset : 0.50 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cerevel Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €519.30 Mil. Cerevel Therapeutics Holdings's Total Assets for the quarter that ended in Mar. 2024 was €1,037.16 Mil.

The historical rank and industry rank for Cerevel Therapeutics Holdings's Equity-to-Asset or its related term are showing as below:

STU:673' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33 Med: 0.7 Max: 0.95
Current: 0.5

During the past 5 years, the highest Equity to Asset Ratio of Cerevel Therapeutics Holdings was 0.95. The lowest was 0.33. And the median was 0.70.

STU:673's Equity-to-Asset is ranked worse than
64.03% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:673: 0.50

Cerevel Therapeutics Holdings Equity-to-Asset Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Equity-to-Asset Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.64

0.86

0.84

0.51

0.54

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial													0.46	0.39	0.33	0.54	0.50

Competitive Comparison of Cerevel Therapeutics Holdings's Equity-to-Asset

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerevel Therapeutics Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's Equity-to-Asset falls into.

Cerevel Therapeutics Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cerevel Therapeutics Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	617.824	/	1140.104
	=

Cerevel Therapeutics Holdings's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	519.299	/	1037.156
	=

Cerevel Therapeutics Holdings (STU:673) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cerevel Therapeutics Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines